Humanigen

Humanigen FCF Growth

Delisted

The Year-over-Year Free Cash Flow Growth of Humanigen (HGENQ) as of Oct 16, 2026 is 58.33 %. In the previous year, Year-over-Year Free Cash Flow Growth was -163.42 % — a change of -135.69% (higher).

FCF Growth

58.33 %

YoY

-135.69%

Last updated:

Year-over-Year Free Cash Flow Growth of Humanigen is 2022 58.33 % . Year-over-Year Free Cash Flow Growth of Humanigen was 2021 -163.42 % . It decreases by -135.69% higher compared to the previous year.

The Humanigen FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2015
19.76 USD
Jan 1, 2016
28.22 USD
Jan 1, 2017
32.01 USD
Jan 1, 2018
56.42 USD
Jan 1, 2019
35.59 USD
Jan 1, 2020
-1,646.75 USD
Jan 1, 2021
-163.42 USD
Jan 1, 2022
58.33 USD
The Humanigen FCF Growth history
YEARFCF GrowthYoY
58.33 %-135.69%
-163.42 %-90.08%
-1,646.75 %-4,727.29%
35.59 %-36.92%
56.42 %+76.24%
32.01 %+13.45%
28.22 %+42.82%
19.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanigen stock

Year-over-Year Free Cash Flow Growth of Humanigen is 58.33 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Humanigen since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Humanigen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Humanigen

All Key Metrics — Humanigen